The Macular Minute Episode 1
with Hani Hasan
Implications of Reducing the Anti-VEGF Treatment Burden
In this 4-minute episode, we are joined by Hani Hasan, a Consultant Ophthalmologist at Newcastle upon Tyne Hospitals NHS Foundation Trust, to discuss the implications of reducing the anti-VEGF treatment burden.
This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.
Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.
Prescribing information for EYLEA® (aflibercept) 2 mg can be found here.
Hani Hasan
Consultant Ophthalmologist with special interest in diabetic eye disease, ocular side effects of medications, ocular coherence tomography, and general retina pathology.
Based at the Royal Victoria Infirmary, Newcastle upon Tyne.
Speaker Disclosures
Speaker and travel grants: AbbVie, Bayer and Roche
References
- EYLEA® 40 mg/mL Summary of Product Characteristics.
- EYLEA® 114.3 mg/mL Summary of Product Characteristics.
PP-EYL-GB-2541 | December 2024